CA2985006C — Stable crystal form of tipiracil hydrochloride and crystallization method for the same
Assigned to Taiho Pharmaceutical Co Ltd · Expires 2022-02-22 · 4y expired
What this patent protects
An objective of the present invention is to obtain a stable crystal form of 5-chloro-6-(2-iminopyrrolidin-1-yl)methy1-2,4(1H,3H)-pyrimidinedione hydrochloride. The present invention provides a crystal of 5-chloro-6-(2-iminopyrrolidin-1-yl)methy1-2,4(1H,3H)-pyrimidinedione hydroch…
USPTO Abstract
An objective of the present invention is to obtain a stable crystal form of 5-chloro-6-(2-iminopyrrolidin-1-yl)methy1-2,4(1H,3H)-pyrimidinedione hydrochloride. The present invention provides a crystal of 5-chloro-6-(2-iminopyrrolidin-1-yl)methy1-2,4(1H,3H)-pyrimidinedione hydrochloride exhibiting characteristic peaks at angles of 10.50, 19.60, 23.70, 26.20 and 31.2 as a diffraction angle (20 0.2 ) in powder X-ray diffraction; pharmaceutical compositions comprising same; and uses of same as a medicament.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.